The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review. (2nd September 2022)

• Record Type: Journal Article
• Authors: Koch, Birgit C.P.; Zhao, Qiaolin; Oosterhoff, Maartje; van Oldenrijk, Jakob; Abdulla, Alan; de Winter, Brenda C.M.; Bos, Koen; Muller, Anouk E.
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 18:Number 9(2022)
• Page Start: 587
• Page End: 600
• Publication Date: 2022-09-02
• Subjects: target-site concentration -- antibiotics -- bone and joint infections -- orthopedic infections -- MIC -- ECOFF -- toxicity -- exposure; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2022.2117607
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction: Currently, antibiotic treatment is often a standard dosing regimen in bone and joint infections (BJI). However, it remains unknown if exposure at the target-site is adequate. The aim of this review is to gain more insight in the relationship between the target site concentration of antibiotic and the minimal inhibitory concentration to target the bacteria in bone and joint infections (BJI). Areas covered: A literature search was performed by Erasmus MC Medical library. Bone, bone tissue and synovial concentration of antibiotics were covered in humans. In addition, we reported number of patients, dose, sampling method, analytical method and tissue and plasma concentrations. We used the epidemiological cutoff value (ECOFF) values of the targeted micro-organisms. If more than 3 publications were available on the antibiotic, we graphically presented ECOFFS values against reported antibiotic concentrations. Expert opinion: For most antibiotics, the literature is sparse. In addition, a lot of variable and total antibiotic concentrations are published. Ciprofloxacin, cefazolin, cefuroxime, vancomycin and linezolid seem to have adequate average exposure if correlating total concentration to ECOFF, when standard dosing is used. With regard to other antibiotics, results are inconclusive. More extensive pharmacokinetic/pharmacodynamic modeling in BJI is needed.